Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
|Videos|August 17, 2021
High patient satisfaction is observed with urology telehealth visits
Author(s)Urology Times staff
Ninety-one percent of patients “felt very comfortable sharing sensitive information with the healthcare provider via the telehealth platform,” says Kara L. Watts, MD.
Advertisement
In this video, Kara L. Watts, MD, discusses findings from the recent Urology study, “Patient Satisfaction with Telephone Versus Video- Televisits: A Cross-Sectional Survey of an Urban, Multiethnic Population,” for which she served as senior author. Watts is an assistant professor of urology at Montefiore Medical Center, Bronx, New York.
Advertisement
Related to this article
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
3
Matching mCSPC treatment to the patient, not just the trial data
4
Variation in PSMA PET Adoption for Prostate Cancer Care
5